2,2,4,4-Tetramethyl-8-nitro-3,4-dihydro-2H-1-benzopyran | 652992-15-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡喃
• 英文名称: 2,2,4,4-Tetramethyl-8-nitro-3,4-dihydro-2H-1-benzopyran
• 英文别名: 2,2,4,4-tetramethyl-8-nitro-3H-chromene
• CAS: 652992-15-9
• 化学式: C13H17NO3
• 分子量: 235.28
• InChiKey: IQEFTMXRZAVAQO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  17
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.54
• 拓扑面积：
  55
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• CHROMAN-SUBSTITUTED, TETRAHYDROQUINOLINE-SUBSTITUTED AND THIOCHROMAN-SUBSTITUTED HETEROAROTINOIDS AS ANTI-CANCER AGENTS
  申请人：THE BOARD OF REGENTS FOR OKLAHOMA STATE UNIVERSITY

  公开号：US20200062711A1

  公开（公告）日：2020-02-27

  Chemical compounds that inhibit cancer cell growth are provided. The compounds are heteroarotinoids and derivatives thereof with oxygen, nitrogen or sulfur in chroman systems, tetrahydroquinoline systems, and tetrahydrothiochroman systems.

  提供了抑制癌细胞生长的化合物。这些化合物是杂环维生素A类化合物及其衍生物，其在色酮系统、四氢喹啉系统和四氢硫色酮系统中含有氧、氮或硫。
• Chroman-substituted, tetrahydroquinoline-substituted and thiochroman-substituted heteroarotinoids as anti-cancer agents
  申请人：THE BOARD OF REGENTS FOR OKLAHOMA STATE UNIVERSITY

  公开号：US10947198B2

  公开（公告）日：2021-03-16

  Chemical compounds that inhibit cancer cell growth are provided. The compounds are heteroarotinoids and derivatives thereof with oxygen, nitrogen or sulfur in chroman systems, tetrahydroquinoline systems, and tetrahydrothiochroman systems.

  提供了抑制癌细胞生长的化学物质。这些化合物是杂芳基类化合物及其衍生物，在铬烷体系、四氢喹啉体系和四氢硫铬烷体系中含有氧、氮或硫。
• METHODS OF TREATMENT WITH COMPOUNDS HAVING RAR $g(a)? RECEPTOR SPECIFIC OR SELECTIVE ACTIVITY
  申请人：Vision Pharmaceuticals L.P.

  公开号：EP0869782A2

  公开（公告）日：1998-10-14
• [EN] METHODS OF TREATMENT WITH COMPOUNDS HAVING RAR alpha RECEPTOR SPECIFIC OR SELECTIVE ACTIVITY<br/>[FR] PROCEDES DE TRAITEMENT AVEC DES COMPOSES AYANT UNE ACTIVITE SPECIFIQUE OU SELECTIVE SUR LES RECEPTEURS RAR alpha
  申请人：——

  公开号：WO1997024116A2

  公开（公告）日：1997-07-10

  [EN] Retinoid compounds which act specifically or selectively on RAR alpha receptor subtypes in preference over RAR beta and RAR GAMMA receptor subtypes, possess desirable pharmaceutical properties associated with retinoids, and are particularly suitable for treatment of tumors, such as acute monocytic leukemia, cervical carcinoma, myeloma, ovarian carcinomas and head and neck carcinomas, without having one or more undesirable side effects of retinoids, such as inducement of weight loss, mucocutaneous toxicity, skin irritation and teratogenicity.
  [FR] L'invention concerne des composés rétinoïdes agissant spécifiquement ou sélectivement sur des sous-types de récepteurs RAR alpha , de préférence sur des sous-types des récepteurs RAR beta et RAR GAMMA . Ils possèdent les propriétés pharmaceutiques souhaitables associées aux rétinoïdes, et sont notamment appropriés pour le traitement de tumeurs, telles que la leucémie monocytaire aiguë, le carcinome du col utérin, le myélome, les carcinomes ovariens et les carcinomes de la tête du col, sans présenter un ou plusieurs des effets secondaires indésirables des rétinoïdes, tels que l'induction d'un amaigrissement, la toxicité mucocutanée, l'irritation cutanée et la tératogénicité.
  [EN] Retinoid compounds which act specifically or selectively on RAR alpha receptor subtypes in preference over RAR beta and RAR GAMMA receptor subtypes, possess desirable pharmaceutical properties associated with retinoids, and are particularly suitable for treatment of tumors, such as acute monocytic leukemia, cervical carcinoma, myeloma, ovarian carcinomas and head and neck carcinomas, without having one or more undesirable side effects of retinoids, such as inducement of weight loss, mucocutaneous toxicity, skin irritation and teratogenicity.